CEFUROXIME injection, powder, for solution

국가: 미국

언어: 영어

출처: NLM (National Library of Medicine)

유효 성분:

CEFUROXIME SODIUM (UNII: R8A7M9MY61) (CEFUROXIME - UNII:O1R9FJ93ED)

제공처:

Hospira, Inc.

관리 경로:

INTRAVENOUS

처방전 유형:

PRESCRIPTION DRUG

치료 징후:

To reduce the development of drug-resistant bacteria and maintain the effectiveness of cefuroxime for injection and other antibacterial drugs, cefuroxime for injection should be used only to treat or prevent infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy. Cefuroxime for injection is indicated for the treatment of patients with infections caused by susceptible strains of the designated organisms in the following diseases: Clinical microbiological studies in skin and skin-structure infections frequently reveal the growth of susceptible strains of both aerobic and anaerobic organisms. Cefuroxime for injection has been used successfully in these mixed infections in which several organisms have been isolated. In certai

제품 요약:

Cefuroxime for injection in the dry state should be stored at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature] and protected from light. Cefuroxime for injection is a dry, white to off-white powder supplied as follows: NDC 0409-0803-01    7.5 grams* per Pharmacy Bulk Package Bottle (Box of 10 Bottles)   *Equivalent to cefuroxime.

제품 특성 요약

CEFUROXIME- CEFUROXIME INJECTION, POWDER, FOR SOLUTION
HOSPIRA, INC.
----------
CEFUROXIME FOR INJECTION, USP
PRESCRIBING INFORMATION
PHARMACY BULK PACKAGE
NOT FOR DIRECT INFUSION
RX ONLY
To reduce the development of drug-resistant bacteria and maintain the
effectiveness of cefuroxime for
injection, USP and other antibacterial drugs, cefuroxime for
injection, USP should be used only to treat
or prevent infections that are proven or strongly suspected to be
caused by bacteria.
DESCRIPTION
Cefuroxime is a semisynthetic, broad-spectrum, cephalosporin
antibiotic for parenteral administration. It
is the sodium salt of (6R,
7R)-3-carbamoyloxymethyl-7-[Z-2-methoxyimino-2-(fur-2-
yl)acetamido]ceph-3-em-4-carboxylate, and it has the following
chemical structure:
The molecular formula is C
H N NaO S, representing a molecular weight of 446.4.
Cefuroxime for injection, USP contains approximately 54.2 mg (2.4 mEq)
of sodium per gram of
cefuroxime activity.
Cefuroxime for injection, USP in sterile crystalline form is supplied
in Pharmacy Bulk Package
equivalent to 7.5 g of cefuroxime as cefuroxime sodium. Solutions of
cefuroxime for injection, USP
range in color from light yellow to amber, depending on the
concentration and diluent used. The pH of
freshly constituted solutions usually ranges from 6 to 8.5.
A pharmacy bulk package is a container of a sterile preparation for
parentral use that contains many
single doses. The contents are intended for use in a pharmacy
admixture service and are restricted to the
preparation of admixtures for intravenous infusion. FURTHER DILUTION
IS REQUIRED BEFORE
USE.
CLINICAL PHARMACOLOGY
After intramuscular (IM) injection of a 750 mg dose of cefuroxime to
normal volunteers, the mean peak
serum concentration was 27 mcg/mL. The peak occurred at approximately
45 minutes (range, 15 to 60
16
15
4
8
minutes). Following IV doses of 750 mg and 1.5 g, serum concentrations
were approximately 50 and
100 mcg/mL, respectively, at 15 minutes. Therapeutic serum
concentrations of approximately 2 mcg/mL
or mo